Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Esomeprazole 40 mg Capsules
NCT05235217Phase 1Completed
- Sponsor
- Future University in Egypt
- Start
- Jun 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esomeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Future University in Egypt. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration Curve from Administration to Last Observed Concentration and 1 more. Started Jun 2021; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05235217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235217.